<DOC>
	<DOC>NCT02538484</DOC>
	<brief_summary>Assess the impact of dietary omega 3 free fatty acids and/or letrozole on obese, postmenopausal breast cancer patients.</brief_summary>
	<brief_title>Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects</brief_title>
	<detailed_description>Prospective, comparative, three arm, short term, non-interventional study with correlative biomarker endpoints. Sixty (60) obese (â‰¥ 30 BMI) newly diagnosed ER+ postmenopausal breast cancer patients will be recruited to participate in a short term (30 day) Phase 0 biomarker evaluation study prior to surgical resection.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>At least 18 years of age. Postmenopausal as confirmed in medical history Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB (Institutional Review Board)/Ethics Committee. Estrogen receptor positive breast cancer. Body mass index of 30 or greater. Consented for tissue collection on CTRC (Cancer Therapy and Research Center) repository 0732 Cachexia Active systemic illness (infection including viral illnesses such as Hepatitis and HIV) Chronic use of NSAIDs (nonsteroidal antiinflammatory drugs) aspirin or omega3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days) Any NSAIDs aspirin or omega3 free fatty acid supplementation within the last 14 days History of medical noncompliance Scheduled date of surgical resection that would limit the amount of time taking the intervention to less than 21 days</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>